![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Thursday, June 28, 2018 8:14:02 PM
I think Glenmark will be our partner for the Unique ADT IR line of products.
I bet Glenmark will also get isradipine when we bring it home in October. We already manufacture it at the Northvale plant, and Glenmark will have it plugged in and ready when STEADY-PDIII results are published in early 2019. Many expect this Phase 3 trial will show isradipine is effective to slow down progression of Parkinson's Disease, and with a million patients and only one competitor, Elite will need a high-caliber partner like Glenmark.
https://seekingalpha.com/article/4182056-elite-pharmaceuticals-inc-eltp-ceo-nasrat-hakim-q4-2018-results-earnings-call-transcript?part=single
Nasrat Hakim:
...the contract with Epic regarding this specific manufacturing and supply agreement expires in October of 2018. We intend to bring all of these products home to Elite and we intend to launch them by 2019.
Carter Ward:
...the Alliance with Glenmark includes the ability to expand and add more products. Glenmark's marketing capabilities and resources are well established and they are significant. Expanding the product lines in our alliance is something both of us are interested in. So, the potential is great, and we're optimistic as to the future of the Elite-Glenmark strategic alliance.
https://www.michaeljfox.org/foundation/news-detail.php?record-pace-recruitment-for-steady-pd-iii-lays-foundation-for-other-investigations
One such study is STEADY-PD III, a Phase III trial evaluating the ability of isradipine (a blood pressure drug) to slow or stop PD progression. This National Institutes of Health (NIH)-funded study, however, completed recruitment six months ahead of schedule, driving a potential new PD therapy forward faster and setting precedent for future investigations.
Isradipine is approved by the U.S. Food and Drug Administration (FDA) to treat high blood pressure. Pre-clinical studies and an MJFF-funded Phase II trial demonstrated isradipine has potential to prevent death of dopamine-producing cells and slow Parkinson's progression. An example of a repurposed therapy in PD, isradipine must still undergo rigorous testing to prove it is safe and efficacious for people with Parkinson's.
Call on God but row away from the rocks.
-Hunter S. Thompson
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM